Finding new treatments for cryptosporidiosis
Active Since: 2012
Contributing to SDGs…




This collaborative project is focused on identifying and progressing lead compounds with potential to treat cryptosporidiosis.
MEMBER COMPANIES
-
AbbVie
Company Profile
PARTNER ORGANISATIONS
-
Academia or research institute
University of Washington Department of Public Health
Objectives
Identify potential new treatments for cryptosporidiosis.
Cryptosporidiosis is a parasitic disease that causes watery diarrhea. It occurs around the world, but is more common in developing countries and primarily affects children and their caregivers, older adults and people who are malnourished or immunocompromised. In developing countries, cryptosporidiosis in early childhood may be associated with subsequent impaired physical and cognitive development.
AbbVie is collaborating with the University of Washington Department of Public Health to study certain Bumped Kinase Inhibitors (BKIs) for safety and efficacy for treating the diseases caused by Cryptosporidium in humans and livestock.
SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing
- 3.3: Communicable Diseases & NTDs
SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals
RESULTS & MILESTONES
Lead compounds have been optimized to avoid safety and toxicity liabilities. Identification of a potential clinical candidate is in progress.
ADDITIONAL INFORMATION
FURTHER READING
Geographic Reach
Global Commitment
Disease Area
Infectious and Parasitic Disease
- Other